Oral Semaglutide Reduces Heart Failure Events in Type 2 Diabetes Patients With Prior HF
A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.